| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 05/13/2004 | CA2504388A1 Quinazolinone compositions for regulation of gene expression related to pathological processes |
| 05/13/2004 | CA2503962A1 Compounds, methods and devices for inhibiting neoproliferative changes in blood vessel walls |
| 05/13/2004 | CA2503624A1 Use of a nitric oxide donor to prevent desensitization of g-protein coupled receptors |
| 05/13/2004 | CA2503381A1 Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| 05/12/2004 | EP1417973A2 Vaccine formulation potentiated by the combination of a dna and an antigen |
| 05/12/2004 | EP1416950A1 Artichoke leaf extracts |
| 05/12/2004 | EP1292303B1 A stable pharmaceutical formulation comprising torsemide modification ii |
| 05/12/2004 | CN1496257A Benzimidazole compounds for modulating igE and inhibiting cellular proliferation |
| 05/12/2004 | CN1495198A Analogs of glucagon-like peptide-1 |
| 05/12/2004 | CN1495169A Pyridine-3-carboxylic acid derivative |
| 05/12/2004 | CN1494920A Soft capsule preparation containing cyclosporin |
| 05/12/2004 | CN1149069C Cleansing composition with separately dispensed cleansing base and benefit base wherein benefit base also comprises surfactant |
| 05/11/2004 | US6734284 Exhibits high affinity for the gfr alpha 3- ret receptor complex and unique subregions in its amino acid sequence |
| 05/11/2004 | US6734186 Phosphodiesterase 2 inhibitor |
| 05/11/2004 | US6734184 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) |
| 05/11/2004 | US6733767 Liquid polymeric compositions for controlled release of bioactive substances |
| 05/08/2004 | CA2512484A1 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| 05/06/2004 | WO2004038428A2 Controlled-release compositions |
| 05/06/2004 | WO2004037997A2 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof |
| 05/06/2004 | WO2004037282A1 The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| 05/06/2004 | WO2004037251A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| 05/06/2004 | WO2004037229A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 05/06/2004 | WO2004037211A2 Taxane metabolites |
| 05/06/2004 | WO2004037208A2 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| 05/06/2004 | WO2004037206A2 Methods for diagnosing and treating pre-term labor |
| 05/06/2004 | WO2004037205A2 LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL |
| 05/06/2004 | WO2004037204A2 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
| 05/06/2004 | WO2004037203A2 Sustained release l-arginine formulations and methods of manufacture and use |
| 05/06/2004 | WO2004037198A2 Antibody-mediated induction of tumor cell death |
| 05/06/2004 | WO2004037196A2 Cytomodulating peptides and methods for treating neurological disorders |
| 05/06/2004 | WO2004037195A2 Treatment of diabetes |
| 05/06/2004 | WO2004037192A2 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases |
| 05/06/2004 | WO2004037190A2 Modified release compositions of milnacipran |
| 05/06/2004 | WO2004037189A2 Methods for vaccinating against malaria |
| 05/06/2004 | WO2004037186A2 Prophylactic treatment methods |
| 05/06/2004 | WO2004037183A2 Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
| 05/06/2004 | WO2004037182A2 Active specific immunotherapy of cancer metastasis |
| 05/06/2004 | WO2004037181A2 Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods |
| 05/06/2004 | WO2004037180A2 Compositions that treat or inhibit pathological conditions associated with inflammatory response |
| 05/06/2004 | WO2004037179A2 Substituted peptides useful in the treatment of alzheimer’s disease |
| 05/06/2004 | WO2004037175A2 Compositions and methods for treating human papillomavirus-mediated disease |
| 05/06/2004 | WO2004037173A2 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | WO2004037169A2 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 05/06/2004 | WO2004037168A2 Treatment of pancreatitis with amylin |
| 05/06/2004 | WO2004037167A2 Methods of treating dry eye disease with lantibiotics |
| 05/06/2004 | WO2004037165A2 Nitric oxide and its biomedical significance |
| 05/06/2004 | WO2004037164A2 Crosslinked compounds and methods of making and using thereof |
| 05/06/2004 | WO2004037160A2 In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound |
| 05/06/2004 | WO2004017918A3 Method of preparing dry powder inhalation compositions |
| 05/06/2004 | WO2002091995A8 Method to induce neovascular formation and tissue regeneration |
| 05/06/2004 | US20040087936 System and method for treating abnormal tissue in an organ having a layered tissue structure |
| 05/06/2004 | US20040087888 Pharmaceutical compounding systems and methods and information management system for same |
| 05/06/2004 | US20040087777 Humanized antibodies that recognize beta amyloid peptide |
| 05/06/2004 | US20040087547 Orally administered antitumor agents |
| 05/06/2004 | US20040086896 Polynucleotides and polypeptides associated with the NF-kB pathway |
| 05/06/2004 | US20040086584 Compositions for lowering blood pressure |
| 05/06/2004 | US20040086583 Anti-angiogenesis effects of morinda citrifolia |
| 05/06/2004 | US20040086580 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response |
| 05/06/2004 | US20040086506 Polyvalent immunogen |
| 05/06/2004 | US20040086453 Compositions, methods, apparatuses, and systems for singlet oxygen delivery |
| 05/06/2004 | EP1415992A1 Diamine derivatives |
| 05/06/2004 | EP1415982A1 Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors |
| 05/06/2004 | EP1414415A2 Nutritional supplements and methods of using same |
| 05/06/2004 | EP1181027B1 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 05/06/2004 | EP0868197B1 Anti-l-selectin antibodies for prevention of multiple organ failure and acute organ damage |
| 05/06/2004 | CA2503383A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 05/06/2004 | CA2503284A1 Sustained release l-arginine formulations and methods of manufacture and use |
| 05/06/2004 | CA2502960A1 Active specific immunotherapy of cancer metastasis |
| 05/06/2004 | CA2502696A1 Compositions and methods for treating human papillomavirus-mediated disease |
| 05/06/2004 | CA2502607A1 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | CA2502600A1 Methods of treating dry eye disease with lantibiotics |
| 05/06/2004 | CA2502268A1 Methods for vaccinating against malaria |
| 05/06/2004 | CA2501677A1 Treatment of diabetes |
| 05/06/2004 | CA2501228A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| 05/06/2004 | CA2500829A1 Prophylactic treatment methods |
| 05/06/2004 | CA2497909A1 Low dose methods for treating disorders in which tnf.alpha. activity is detrimental |
| 05/05/2004 | CN1494429A Aguatic animal treatment method and composition containing pimenta extract |
| 05/05/2004 | CN1494420A Compounds and compositions for delivering active agents |
| 05/05/2004 | CN1493308A Preparation technology of sugarless small radix bupleuri granular agent |
| 05/05/2004 | CN1148360C Intermediate for preparing cascade polymeric ligand usable as contrast medium |
| 05/05/2004 | CN1148350C Novel VLA-4 inhibitor: oMePUPA-V |
| 05/05/2004 | CN1148226C Aqueous risperidone formulations |
| 05/04/2004 | US6730783 Reacting aminoguanidine with carbonyl compound to form amidinohydrazone; reduction; reacting with alkoxyamine; guanidinylation; anticoagulants |
| 05/04/2004 | US6730695 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for V1b and V1a arginine-vasopressin receptors |
| 05/04/2004 | US6730690 Delaying the onset or reducing the risk of developing atherosclerosis in a human patient comprising administering to said patient an effective amount of a compound of invention and an hmg-coa reductase inhibitor |
| 05/04/2004 | US6730332 Synergistic aqueous extract from fruits of terminalia chebula, bark of albizia lebbeck, terminalia bellerica and emblica officinalis |
| 04/29/2004 | WO2004035027A1 Pharmaceutical formulation of olanzapine |
| 04/29/2004 | WO2004035008A2 Treatment of infections and other disorders |
| 04/29/2004 | WO2004035007A2 Transmucosal administration of aggregated antigens |
| 04/29/2004 | WO2004035006A2 Methods and compositions for immunization against hiv |
| 04/29/2004 | WO2004035005A2 Three layer tear formulation |
| 04/29/2004 | WO2004035002A2 Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
| 04/29/2004 | WO2004035000A2 Enhancement of sleep with t-type calcium channel antagonists |
| 04/29/2004 | WO2004034999A2 Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain |
| 04/29/2004 | WO2004034996A2 TREATING ALCOHOL AND OR SUBSTANCE ABUSE BY ANTAGONIZING α 2 ADRENERGIC RECEPTORS WITH WEAK DOPAMINE BLOCKING |
| 04/29/2004 | WO2004034995A2 Methods and reagents for inducing immunity |
| 04/29/2004 | WO2004034993A2 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor |
| 04/29/2004 | WO2004034992A2 Encapsulation and deaggregation of polyene antibiotics using poly(ethylene glycol)-phospholipid micelles |
| 04/29/2004 | WO2004034987A2 Treatment for reactive arthritis or bursitis |
| 04/29/2004 | WO2004034985A2 Chemical compounds |